NEUTRISCI’S NEUENERGY® LAUNCHES IN QUEBEC
VANCOUVER, BC – (Marketwired – July 20, 2017) – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX VENTURE: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that neuenergy® is now available at Sobeys gas bars and convenience stores in Quebec.
Sobeys Inc. and Safeway Canada are wholly-owned subsidiaries of Empire Company Limited (“Empire”), and have been distributing neuenergy in other provinces for several months now. Empire is the second largest food retailer in Canada, with over 260 Sobeys and 183 Safeway supermarkets operating in Canada with an additional 1,200 stores operating under banners such as IGA extra, Thrifty Foods, IGA, Foodland, FreshCo, Price Chopper, Lawton Drugs, Rachelle-Béry, Needs, Marché Bonichoix and Les Marchés Tradition.
NeutriSci President Mr. Glen Rehman stated, “We are pleased to announce increased distribution with Sobeys, one of Canada’s preeminent retail groups. With neuenergy now available in Quebec, we will begin implementing national marketing campaigns. These new distribution outlets are ultimately increasing our revenue and market presence.”
Neuenergy® is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products.
Pursuant to the Company’s marketing and branding agreement with Venture Communications Inc., the Company also announces that it will settle outstanding indebtedness of $65,000 through the issuance of 433,333 common shares at a deemed price of $0.15 per share. The settlement remains subject to the approval of the TSX Venture Exchange. All shares issued in the settlement will be subject to a four-month-and-one-day statutory hold period.
To find out more about neuenergy®, please visit www.getneuenergy.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
NeutriSci International Inc.
Tel: (403) 264-6320
About NeutriSci International Inc.: NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
With the recent formation of Ambarii, a joint venture partnership with Lexaria Bioscience Corp., NeutriSci is expanding its reach into the burgeoning cannabinoid industry.
For more information, please visit: www.neutrisci.com or www.ambariicorp.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward- looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.